Anti-biofilm Wound Dressing Market Size, Share | Report 2023-2032
The global anti-biofilm wound dressing market was surpassed at USD 714.80 million in 2022 and is expected to hit around USD 1,794.22 million by 2032, growing at a CAGR of 9.64% from 2023 to 2032.
Key Pointers
| Report Coverage | Details |
| Market Size in 2022 | USD 714.80 million |
| Revenue Forecast by 2032 | USD 1,794.22 million |
| Growth rate from 2023 to 2032 | CAGR of 9.64% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Companies Covered | ConvaTec Inc.; Smith & Nephew PLC; Urgo Medical; Coloplast; 3M; Mölnlycke Health Care AB; Imbed Biosciences; Next Science; B. Braun Melsungen AG; Lohmann & Rauscher |
The increasing incidence of chronic diseases such as diabetes, cancer, and other autoimmune diseases is anticipated to increase the incidence rate of chronic and acute wounds across the globe. Factors such as antimicrobial resistance, unhealthy & sedentary lifestyles, and tobacco & alcohol consumption are contributing to the rising prevalence of non-communicable diseases. For instance, according to the CDC’s National Diabetes Statistics report of 2020, the number of diabetes patients has increased to an estimated 34.2 million, which comprises about 10.5% of the total population. According to a similar report, an estimated 26.8 million people have been diagnosed with diabetes, whereas 7.3 million people had diabetes and were yet to be diagnosed.
Chronic wounds and surgical wounds all have a deleterious impact on wound recovery. The growing geriatric population, rising prevalence of traumatic wounds, an increasing number of surgeries, and rising incidence of illnesses, such as obesity & diabetes, are among the factors contributing to the rising prevalence of chronic wounds over the last decade.
According to the U.S. CDC, 6 in 10 adults are suffering from a chronic disease and 4 in 10 adults are suffering from two or more chronic diseases in the U.S. Furthermore, chronic diseases are the leading cause of disability & death and a key contributor to the country’s USD 3.5 trillion annual healthcare costs. As a result of the rising prevalence of chronic conditions, the number of surgeries being performed has increased. Wound dressing products such as silver-based wound dressing are increasingly being used to prevent surgical site infections.
Most surgical wounds after cancer surgery are generally large in size & deep, producing exudate that requires regular management. Anti-biofilm wound dressing products such as silver, and iodine-based wound dressings help to manage large wounds, thus, reducing the risk of infection. Therefore, the rising incidence of chronic diseases is expected to boost the demand for the products, thereby propelling the growth of the market over the forecast period.
Increasing incidence of burns, trauma events, and road accidents across the globe is anticipated to drive market growth. For instance, as per Association for Safe International Road Travel, approximately, 1.35 million people die every year in a road crash, whereas on average 3,700 people lose their lives every day on the road. Thus, the rising number of accidents is expected to boost the demand for enzymatic wound debridement products, which is expected to lead to considerable growth in the industry over the forecast period.
Market Segmentations:
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Anti-biofilm Wound Dressing Market
5.1. COVID-19 Landscape: Anti-biofilm Wound Dressing Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Anti-biofilm Wound Dressing Market, By Mode of Mechanism
8.1. Anti-biofilm Wound Dressing Market, by Mode of Mechanism, 2023-2032
8.1.1 Physical
8.1.1.1. Market Revenue and Forecast (2019-2032)
8.1.2. Chemical
8.1.2.1. Market Revenue and Forecast (2019-2032)
8.1.3. Biological
8.1.3.1. Market Revenue and Forecast (2019-2032)
Chapter 9. Global Anti-biofilm Wound Dressing Market, By Application
9.1. Anti-biofilm Wound Dressing Market, by Application, 2023-2032
9.1.1. Chronic Wounds
9.1.1.1. Market Revenue and Forecast (2019-2032)
9.1.2. Acute Wounds
9.1.2.1. Market Revenue and Forecast (2019-2032)
Chapter 10. Global Anti-biofilm Wound Dressing Market, By End-use
10.1. Anti-biofilm Wound Dressing Market, by End-use, 2023-2032
10.1.1. Hospitals
10.1.1.1. Market Revenue and Forecast (2019-2032)
10.1.2. Specialty Clinics
10.1.2.1. Market Revenue and Forecast (2019-2032)
10.1.3. Home Healthcare
10.1.3.1. Market Revenue and Forecast (2019-2032)
10.1.4. Others
10.1.4.1. Market Revenue and Forecast (2019-2032)
Chapter 11. Global Anti-biofilm Wound Dressing Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Mode of Mechanism (2019-2032)
11.1.2. Market Revenue and Forecast, by Application (2019-2032)
11.1.3. Market Revenue and Forecast, by End-use (2019-2032)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Mode of Mechanism (2019-2032)
11.1.4.2. Market Revenue and Forecast, by Application (2019-2032)
11.1.4.3. Market Revenue and Forecast, by End-use (2019-2032)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Mode of Mechanism (2019-2032)
11.1.5.2. Market Revenue and Forecast, by Application (2019-2032)
11.1.5.3. Market Revenue and Forecast, by End-use (2019-2032)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Mode of Mechanism (2019-2032)
11.2.2. Market Revenue and Forecast, by Application (2019-2032)
11.2.3. Market Revenue and Forecast, by End-use (2019-2032)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Mode of Mechanism (2019-2032)
11.2.4.2. Market Revenue and Forecast, by Application (2019-2032)
11.2.4.3. Market Revenue and Forecast, by End-use (2019-2032)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Mode of Mechanism (2019-2032)
11.2.5.2. Market Revenue and Forecast, by Application (2019-2032)
11.2.5.3. Market Revenue and Forecast, by End-use (2019-2032)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Mode of Mechanism (2019-2032)
11.2.6.2. Market Revenue and Forecast, by Application (2019-2032)
11.2.6.3. Market Revenue and Forecast, by End-use (2019-2032)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Mode of Mechanism (2019-2032)
11.2.7.2. Market Revenue and Forecast, by Application (2019-2032)
11.2.7.3. Market Revenue and Forecast, by End-use (2019-2032)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Mode of Mechanism (2019-2032)
11.3.2. Market Revenue and Forecast, by Application (2019-2032)
11.3.3. Market Revenue and Forecast, by End-use (2019-2032)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Mode of Mechanism (2019-2032)
11.3.4.2. Market Revenue and Forecast, by Application (2019-2032)
11.3.4.3. Market Revenue and Forecast, by End-use (2019-2032)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Mode of Mechanism (2019-2032)
11.3.5.2. Market Revenue and Forecast, by Application (2019-2032)
11.3.5.3. Market Revenue and Forecast, by End-use (2019-2032)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Mode of Mechanism (2019-2032)
11.3.6.2. Market Revenue and Forecast, by Application (2019-2032)
11.3.6.3. Market Revenue and Forecast, by End-use (2019-2032)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Mode of Mechanism (2019-2032)
11.3.7.2. Market Revenue and Forecast, by Application (2019-2032)
11.3.7.3. Market Revenue and Forecast, by End-use (2019-2032)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Mode of Mechanism (2019-2032)
11.4.2. Market Revenue and Forecast, by Application (2019-2032)
11.4.3. Market Revenue and Forecast, by End-use (2019-2032)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Mode of Mechanism (2019-2032)
11.4.4.2. Market Revenue and Forecast, by Application (2019-2032)
11.4.4.3. Market Revenue and Forecast, by End-use (2019-2032)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Mode of Mechanism (2019-2032)
11.4.5.2. Market Revenue and Forecast, by Application (2019-2032)
11.4.5.3. Market Revenue and Forecast, by End-use (2019-2032)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Mode of Mechanism (2019-2032)
11.4.6.2. Market Revenue and Forecast, by Application (2019-2032)
11.4.6.3. Market Revenue and Forecast, by End-use (2019-2032)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Mode of Mechanism (2019-2032)
11.4.7.2. Market Revenue and Forecast, by Application (2019-2032)
11.4.7.3. Market Revenue and Forecast, by End-use (2019-2032)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Mode of Mechanism (2019-2032)
11.5.2. Market Revenue and Forecast, by Application (2019-2032)
11.5.3. Market Revenue and Forecast, by End-use (2019-2032)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Mode of Mechanism (2019-2032)
11.5.4.2. Market Revenue and Forecast, by Application (2019-2032)
11.5.4.3. Market Revenue and Forecast, by End-use (2019-2032)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Mode of Mechanism (2019-2032)
11.5.5.2. Market Revenue and Forecast, by Application (2019-2032)
11.5.5.3. Market Revenue and Forecast, by End-use (2019-2032)
Chapter 12. Company Profiles
12.1. ConvaTec Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Smith & Nephew PLC
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Urgo Medical
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Coloplast
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. 3M
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Mölnlycke Health Care AB
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Imbed Biosciences
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Next Science
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. B. Braun Melsungen AG
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Lohmann & Rauscher
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers